Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis

Related Experiment Videos

Oliva Ortiz-Alvarez1, Kimberly Morishita, Glenda Avery

  • 1Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

The Journal of Rheumatology
|December 1, 2004
PubMed
Abstract

Insights

Routine blood tests for monitoring methotrexate toxicity in children with juvenile idiopathic arthritis (JIA) may be too frequent. Most abnormal results were transient and linked to viral infections, suggesting less frequent monitoring may suffice.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Toxicology
  • Pharmacovigilance

Background:

  • Methotrexate (MTX) is a cornerstone therapy for juvenile idiopathic arthritis (JIA).
  • Monitoring for MTX-related toxicity is crucial, guided by American College of Rheumatology (ACR) guidelines.
  • Current guidelines recommend frequent laboratory monitoring.

Purpose of the Study:

  • To evaluate the clinical utility of ACR guidelines for monitoring MTX-related toxicity in pediatric JIA patients.
  • To determine the actual frequency and nature of significantly abnormal blood tests (SABT) in this population.

Main Methods:

  • Prospective monitoring of 89 children with JIA treated with MTX.
  • Monthly assessment of liver enzymes (AST, ALT), complete blood count (CBC), and differential blood count.
  • Defined SABT criteria including elevated liver enzymes, low granulocyte/lymphocyte counts, or decreased hemoglobin.

Main Results:

  • 40% of patients experienced at least one SABT (14% liver, 26% hematologic).
  • 95% of SABTs were associated with viral infections; abnormalities normalized after MTX dose withholding.
  • No significant differences in MTX dose, duration, or concurrent medications were found between patients with and without SABT.

Conclusions:

  • The frequency of routine blood tests recommended by ACR guidelines may be excessive for monitoring MTX toxicity in JIA.
  • Less frequent monitoring could be considered, balancing safety with resource utilization.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...